

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C07K 16/28, 16/46, A61K 39/395, C12N 5/10, 15/13, 15/64	A1	(11) International Publication Number: WO 97/31024 (43) International Publication Date: 28 August 1997 (28.08.97)
(21) International Application Number: PCT/GB97/00472 (22) International Filing Date: 20 February 1997 (20.02.97) (30) Priority Data: 9603507.6 20 February 1996 (20.02.96) GB (71) Applicant (for all designated States except US): ISIS INNOVATION LIMITED [GB/GB]; 2 South Parks Road, Oxford OX1 3UB (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): WALDMANN, Herman [GB/GB]; 4 Apsley Road, Oxford OX2 7QY (GB). GILLILAND, Lisa, Kim [US/GB]; 23 Harbord Road, Oxford OX2 8LH (GB). TONE, Masahide [JP/GB]; 18 Rosamund Road, Wolvercote, Oxford OX2 8NU (GB). FREWIN, Mark, Raymond [GB/GB]; 15 Harley Road, Oxford OX2 0HS (GB). WALSH, Louise [GB/GB]; 56 Victoria Park, Cambridge CB4 3EL (GB). (74) Agent: PRIVETT, Kathryn, L.; Stevens, Hewlett & Perkins, 1 Serjeants' Inn, Fleet Street, London EC4Y 1LL (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ANTIBODY VARIANTS		
(57) Abstract		
<p>This invention relates to an antibody which is a modified version of a therapeutic antibody with affinity for a cell-surface antigen, said antibody having reduced affinity for the antigen compared with the therapeutic antibody as a result of a modification or modifications to the antibody molecule, wherein the antibody is capable of inducing immunological tolerance to the therapeutic antibody. The invention further relates to a method of inducing immunological tolerance to a therapeutic antibody, comprising administering to a patient an antibody which is a modified version of the therapeutic antibody and which has reduced affinity for the antigen as compared with the therapeutic antibody.</p>		